<?xml version="1.0" encoding="UTF-8"?>
<p>The pathogenesis of Covid‐19 may include antibody‐dependent enhancement (ADE).
 <xref rid="rmv2161-bib-0099" ref-type="ref">
  <sup>99</sup>
 </xref> Mechanistically, ADE involves the cross‐linking of virus and antibody or virus and activated complement component complexes through interactions with cellular molecules, such as Fc and complement receptors or cell surface molecules, to promote internalization of the virus and increase the infection of monocytic and granulocytic cells.
 <xref rid="rmv2161-bib-0100" ref-type="ref">
  <sup>100</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0101" ref-type="ref">
  <sup>101</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0102" ref-type="ref">
  <sup>102</sup>
 </xref> Although the role of ADE has been reported in numerous contemporary viral diseases affecting humans and animals,
 <xref rid="rmv2161-bib-0103" ref-type="ref">
  <sup>103</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0104" ref-type="ref">
  <sup>104</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0105" ref-type="ref">
  <sup>105</sup>
 </xref> dengue is arguably the best disease model to study this phenomenon.
 <xref rid="rmv2161-bib-0106" ref-type="ref">
  <sup>106</sup>
 </xref> DENV homotypic infection confers long‐lasting and even life‐time immunity. However, cross‐neutralizing antibodies against re‐infection of different serotypes are short‐lived.
 <xref rid="rmv2161-bib-0107" ref-type="ref">
  <sup>107</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0108" ref-type="ref">
  <sup>108</sup>
 </xref> At sub‐neutralizing concentrations, these heterotypic antibodies may trigger ADE and are associated with higher odds of more severe forms of secondary infection when present at relatively low levels in children.
 <xref rid="rmv2161-bib-0109" ref-type="ref">
  <sup>109</sup>
 </xref> This condition affects the development of a dengue vaccine, given that vaccination is considered to mimic a primary infection. Indeed, the diminishing levels of antibodies may pose a serious risk of ADE occurrence in children with secondary infections
 <xref rid="rmv2161-bib-0110" ref-type="ref">
  <sup>110</sup>
 </xref> and may cause alert for vaccine‐induced enhancement of viral infection.
 <xref rid="rmv2161-bib-0111" ref-type="ref">
  <sup>111</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0112" ref-type="ref">
  <sup>112</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0113" ref-type="ref">
  <sup>113</sup>
 </xref>
</p>
